News

Boston Scientific Initiates Trial to Evaluate WATCHMAN FLX™ Left Atrial Appendage Closure Device as First-Line Treatment for People at Risk of Stroke
October 29, 2020
Trial to study next-generation device as treatment alternative to NOACs for broader population of patients with non-valvular atrial fibrillation
VivaLNK Extends its Ambulatory Medical Wearable Data Platform to Include Continuous SpO2 Monitoring
October 29, 2020
Solution offers continuous monitoring of four basic human vitals plus ECG rhythm for ambulatory and remote patient monitoring applications
Maxim Integrated's Health Sensor Platform 3.0 Reduces Development Time of Healthcare Wearables by At Least Six Months
October 29, 2020
MAXREFDES104# is a wrist form factor reference design ready to collect blood oxygen, ECG, heart rate, body temperature and activity data
Decreases in Americans' Primary Care Visits May Lead to Late Diagnoses of Potentially Serious Conditions[1]
October 27, 2020
‘No Time to Wait’ campaign launches to educate about symptoms of Atrial Fibrillation (AFib), Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
RetinalGeniX™ Technologies Announces RetinalCam™ a Home Monitoring & Physician Alert System
October 27, 2020
Regular central retina monitoring with the RetinalCam™ Home Monitoring & Physician Alert System will be extremely valuable for high-risk individuals, whose risk factors include: obesity, earliest signs of diabetes, cardiovascular disorders, macular degeneration, neurological disorders, ocular tumors, physical disabilities, COVID-19, and weakened immune systems.
Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO® (rivaroxaban) in Patients with Peripheral Artery Disease
October 27, 2020
The Janssen Pharmaceutical Companies of Johnson & Johnson announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD).
New Model Predicts Which Patients With Kidney Disease May Develop Heartbeat Irregularities
October 26, 2020
A new model that uses machine learning, which is a type of artificial intelligence, may help predict which patients with kidney disease are at especially high risk of developing heartbeat irregularities. The findings come from a study that will be presented online during ASN Kidney Week 2020 Reimagined, October 19-October 25.
The remedē® System.
Transvenous Phrenic Nerve Stimulation (The remedē System) Shows Sustained Safety and Efficacy Through 5 Years
October 23, 2020
Trial results showed consistent improvement in sleep disordered breathing, arousals, sleep architecture, and daytime sleepiness through 5 years.
Community Wellness Launches in California to Bring Remote Patient Monitoring Service to Older Adults with Cardiovascular Disease and Related Chronic Conditions
October 23, 2020
Remote Patient Monitoring service for consumers delivers medical devices, mobile application and monthly video check-in with licensed physician to drive improved health outcomes Company has entered into a strategic clinical relationship with Richard A. Levy, MD, FACC; providing remote patient monitoring services to 1000+ patients
LIVMOR receives FDA clearance for the world’s first prescriptible wearable for continuous heart monitoring. In a multicenter clinical trial with 269 enrolled patients, the LIVMOR Halo™ was 100% sensitive in identifying patients with AF and 93% specific in identifying patients without AF.
LIVMOR Receives FDA Clearance for the World's First Prescriptible Wearable for Continuous Heart Monitoring
October 23, 2020
Availability of physician-prescribed cardiac monitoring system will significantly improve screening and treatment of atrial fibrillation and other chronic heart conditions.